Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
N118984-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $155.90 | |
N118984-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $547.90 | |
N118984-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $2,466.90 | |
N118984-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $8,877.90 |
Melanocortin receptor agonist
Synonyms | [Nle4,D-Phe7]-a-MSH | Msh, 4-nle-7-phe-alpha- | AC-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 | alpha-Melanotropin, 4-L-norleucine-7-D-phenylalanine- | CUV 1647 | Melanotan-1 | 4-Nle-7-phe-alpha-msh | .ALPHA.-MELANOTROPIN (SWINE), 4-L-NORLE |
---|---|
Specifications & Purity | Moligand™, ≥95%(HPLC) |
Biochemical and Physiological Mechanisms | Synthetic analog ofα-MSH that is an agonist at melanocortin receptors (Kivalues are 0.085, 0.4, 3.8 and 5.1 nM for MC1, MC3, MC4and MC5receptors respectively). |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of MC 1 receptor;Agonist of MC 3 receptor;Agonist of MC 4 receptor;Agonist of MC 5 receptor |
Note | 1mg卖完停产,不再备货 |
Product Description | Amino Acid Sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
---|---|
INCHI | InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1 |
InChi Key | UAHFGYDRQSXQEB-LEBBXHLNSA-N |
Canonical SMILES | CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C |
Isomeric SMILES | CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C |
PubChem CID | 16154396 |
Molecular Weight | 1646.85 |
CAS Registry No. | 75921-69-6 |
---|---|
Wikipedia | Afamelanotide |
GPCRdb Ligand | afamelanotide |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L1811159 | Certificate of Analysis | Sep 20, 2022 | N118984 |
L1811158 | Certificate of Analysis | Sep 20, 2022 | N118984 |
I1428026 | Certificate of Analysis | Jul 19, 2022 | N118984 |
G1809007 | Certificate of Analysis | May 13, 2022 | N118984 |
G1809006 | Certificate of Analysis | May 13, 2022 | N118984 |
Solubility | Soluble to 0.60 (mg/mL) in water} |
---|
1. Minder EI, Barman-Aksoezen J, Schneider-Yin X. (2017) Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.. Clin Pharmacokinet, 56 (8): (815-823). [PMID:28063031] [10.1021/op500134e] |
2. Kim ES, Garnock-Jones KP. (2016) Afamelanotide: A Review in Erythropoietic Protoporphyria.. Am J Clin Dermatol, 17 (2): (179-85). [PMID:26979527] [10.1021/op500134e] |
3. Luger TA, Böhm M. (2015) An α-MSH analog in erythropoietic protoporphyria.. J Invest Dermatol, 135 (4): (929-931). [PMID:25785940] [10.1021/op500134e] |
4. McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH. (2018) Afamelanotide in the Treatment of Dermatologic Disease. Skin Therapy Lett, 23 (6): (6-10). [PMID:30517779] [10.1021/op500134e] |